RxDoctor Payments Data

Ronald McLendon, MD

Family Medicine · New Orleans, LANPI 1013151091

Payments from drug & device makers

$912in general payments, 2019–2025

Across 49 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$116
  • GSK$112
  • Lilly USA, LLC$101
  • AstraZeneca$98
  • Amgen$98
  • Otsuka America Pharmaceutical, Inc.$65
  • plus $322 from 12 others

What the payments were for

  • Food & beverage$912100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$912 in reported general payments places this provider in the 55th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$206,689
Medicare patients
238
Services billed
2,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban533$187,377
OzempicSemaglutide137$153,809
JardianceEmpagliflozin260$148,327
QutenzaCapsaicin/Skin Cleanser43$137,305
TrulicityDulaglutide94$100,738
EnbrelEtanercept12$89,916
Trelegy ElliptaFluticasone/Umeclidin/Vilanter107$71,471
Invega SustennaPaliperidone Palmitate24$63,660
BiktarvyBictegrav/Emtricit/Tenofov Ala13$54,554
JanuviaSitagliptin Phosphate121$47,404
Repatha SureclickEvolocumab57$43,570
IngrezzaValbenazine Tosylate11$41,594
MyrbetriqMirabegron128$40,388
LinzessLinaclotide33$32,761
MounjaroTirzepatide19$25,306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$187,377533 claims
Boehringer IngelheimJardiance, Tradjenta$46$167,541306 claims
Novo NordiskOzempic$18$153,809137 claims
Lilly USA, LLCTrulicity, Mounjaro$101$126,044113 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$112$100,022169 claims
AmgenEnbrel$98$89,91612 claims
Astellas Pharma US IncMyrbetriq$17$40,388128 claims
AbbVieLinzess$116$32,76133 claims
Otsuka America Pharmaceutical, Inc.Rexulti$65$22,39131 claims
AstraZenecaFarxiga, Brilinta$98$21,66664 claims
NovartisEntresto$33$14,62042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →